

Supplementary Information

Palladium-catalyzed enantioselective carbonylation toward N-N axially chiral amides

Ke-Jiao Li,^{#,a} Ying-Ying Geng,^{#,a} Fu-Jian Zhang,^a Xin-Yue Li,^a Jing-Wen Liu,^a Cheng-Gui Wu,^{*,a}
Cheng-Tao Feng^{*,a} and Fan Teng^{*,a}

^a *School of Pharmacy, Anhui University of Chinese Medicine; Anhui academy of Chinese medicine, Hefei 230012, China*

E-mail: cgwu@ahtcm.edu.cn; fengct@mail.ustc.edu.cn; teng_fan@qq.com

Table of Contents

1. General Information	S3
2. Experimental Procedures	S4
3. Synthetic Applications	S9
4. DFT (density functional theory) calculations	S10
5. Preparation of Starting Materials	S14
6. Characterization Data for the Products	S24
7. Copies of the ^1H NMR and ^{13}C NMR Spectra	S37

1. General Information

Unless otherwise noted, all chemicals were purchased from commercial suppliers and used without further purification. ^1H NMR and ^{13}C NMR spectra were recorded at ambient temperature on a 600 MHz spectrometer (150 MHz for ^{13}C NMR). NMR experiments are reported in units, parts per million (ppm), and were referenced to CDCl_3 (7.26 or 77.0 ppm) and DMSO (2.50 or 39.5 ppm) as the internal standard. The coupling constants J are given in Hertz. Column chromatography was performed using EM silica gel 60 (200–300 mesh). ABSciex5600plusQTOF HR mass spectrometer equipped with an ESI source was used for analysis.

2. Experimental Procedures

2.1 General procedure (0.1 mmol scale)


An oven-dried 25 mL Schlenk tube charged with **1a** (0.1 mmol), Pd(bpy)Cl₂ (10 mol%, 3.3 mg), **L3** (20 mol%, 8.8 mg), DABCO (0.2 mmol, 22.40 mg), 5 Å MS (160 mg), and Hantzsch ester (0.12 mmol, 30.4 mg), 1.5 mL of toluene added. Then, the tube was vacuumed and refilled with CO and was placed in 30 °C oil-bath for 48 h. The crude reaction mixture was concentrated in vacuo and the residue was purified by silica gel flash column chromatography to afford the corresponding products.


2.2 General procedure (1.0 mmol scale)

An oven-dried 50 mL Schlenk tube charged with **1a** (1.0 mmol), Pd(bpy)Cl₂ (10 mol%, 33.0 mg), **L3** (20 mol%, 88.0 mg), DABCO (2.0 mmol, 224.0 mg), 5 Å MS (1.6 g), and Hantzsch ester (1.2 mmol, 304.0 mg), 15 mL of toluene added. Then, the tube was vacuumed and refilled with CO and was placed in 30 °C oil-bath for 60 h. The crude reaction mixture was concentrated in vacuo and the residue was purified by silica gel flash column chromatography to afford the corresponding products in 65% yield and 81% ee.

2.3 Detailed Information of Conditions Optimization for 2a^a

Table S1:






Entry	Catalyst	Base	Solvent	T / °C	Yield / %	ee / %
1	Pd(OAc) ₂ (PPh ₃) ₂	K ₂ CO ₃	Ph-Me	30	36	65
2	Pd(PivO) ₂	K ₂ CO ₃	Ph-Me	30	41	57
3	Pd(acac) ₂	K ₂ CO ₃	Ph-Me	30	35	63
4	Pd(PPh ₃) ₂ Cl ₂	K ₂ CO ₃	Ph-Me	30	26	59
5	Pd(dppf)Cl ₂	K ₂ CO ₃	Ph-Me	30	21	--
6	Pd(TMEDA)Cl ₂	K ₂ CO ₃	Ph-Me	30	27	77
7	Pd(MeCN) ₂ Cl ₂	K ₂ CO ₃	Ph-Me	30	37	9
8	Pd(dppp)Cl ₂	K ₂ CO ₃	Ph-Me	30	trace	--
9	Pd(PCy ₃) ₂ Cl ₂	K ₂ CO ₃	Ph-Me	30	N, R	--
10	PdCl ₂	K ₂ CO ₃	Ph-Me	30	33	68
11	Pd(OAc) ₂	K ₂ CO ₃	Ph-Me	30	55	77
12	Pd ₂ (dba) ₃	K ₂ CO ₃	Ph-Me	30	58	71
13	Pd(hfac) ₂	K ₂ CO ₃	Ph-Me	30	43	37
14	Pd(TFA) ₂	K ₂ CO ₃	Ph-Me	30	31	72
15	RhCl(PPh ₃) ₃	K ₂ CO ₃	Ph-Me	30	N, R	--
16	FeSO ₄	K ₂ CO ₃	Ph-Me	30	N, R	--
17	CuCl ₂	K ₂ CO ₃	Ph-Me	30	N, R	--
18	CuI	K ₂ CO ₃	Ph-Me	30	N, R	--
19	Ag(OAc)	K ₂ CO ₃	Ph-Me	30	N, R	--
20	[Ir(ppy) ₂ Cl] ₂	K ₂ CO ₃	Ph-Me	30	N, R	--
21	Pd(bpy)Cl ₂	K ₂ CO ₃	Ph-Me	30	30	78
22	Pd(bpy)Cl ₂	pyridine	Ph-Me	30	26	57
23	Pd(bpy)Cl ₂	DBU	Ph-Me	30	N, R	--
24	Pd(bpy)Cl ₂	KOtBu	Ph-Me	30	trace	--

25	Pd(bpy)Cl ₂	NaOtBu	Ph-Me	30	trace	--
26	Pd(bpy)Cl ₂	NaOH	Ph-Me	30	trace	--
27	Pd(bpy)Cl ₂	Na ₂ CO ₃	Ph-Me	30	38	53
28	Pd(bpy)Cl ₂	Cs ₂ CO ₃	Ph-Me	30	36	69
29	Pd(bpy)Cl ₂	Et ₃ N	Ph-Me	30	< 10	73
30	Pd(bpy)Cl ₂	DIPEA	Ph-Me	30	13	51
31 ^b	Pd(bpy)Cl ₂	DABCO	Ph-Me	30	46 (77) ^b	81 (81) ^b
32	Pd(bpy)Cl ₂	DABCO	MeCN	30	trace	--
33	Pd(bpy)Cl ₂	DABCO	MTBE	30	20	57
34	Pd(bpy)Cl ₂	DABCO	DCB	30	27	60
35	Pd(bpy)Cl ₂	DABCO	MeOH	30	trace	--
36	Pd(bpy)Cl ₂	DABCO	DCM	30	60	30
37	Pd(bpy)Cl ₂	DABCO	acetone	30	< 10	51
38	Pd(bpy)Cl ₂	DABCO	Ph-CF ₃	30	47	66
39	Pd(bpy)Cl ₂	DABCO	Ph-F	30	50	67
40	Pd(bpy)Cl ₂	DABCO	Ph-Cl	30	48	73
41	Pd(bpy)Cl ₂	DABCO	Ph-Br	30	44	60
42	Pd(bpy)Cl ₂	DABCO	o-Xylene	30	49	60
43	Pd(bpy)Cl ₂	DABCO	Mesitylene	30	36	71
44	Pd(bpy)Cl ₂	DABCO	CHCl ₃	30	33	70
45	Pd(bpy)Cl ₂	DABCO	Et ₂ O	30	trace	--
46	Pd(bpy)Cl ₂	DABCO	DME	30	-	-
47	Pd(bpy)Cl ₂	DABCO	Ph-Me: DMSO (1:1)	30	22	61
48	Pd(bpy)Cl ₂	DABCO	Ph-Me: MeCN (1:1)	30	45	67
49	Pd(bpy)Cl ₂	DABCO	Ph-Me: acetone (1:1)	30	36	73
50	Pd(bpy)Cl ₂	DABCO	Ph-Me: DCM (1:1)	30	47	71
51	Pd(bpy)Cl ₂	DABCO	Ph-Me: DMF (1:1)	30	N, R	--
52	Pd(bpy)Cl ₂	DABCO	Ph-Me: DMA (1:1)	30	N, R	--
53	Pd(bpy)Cl ₂	DABCO	Ph-Me	40	44	77
54	Pd(bpy)Cl ₂	DABCO	Ph-Me	50	43	73
55	Pd(bpy)Cl ₂	DABCO	Ph-Me	60	47	69

Pd(bpy)Cl ₂	DABCO	Ph-Me	70	49	65
^a Reaction conditions: 1a (0.10 mmol), Cat (10 mol%), ligand (20 mol%), base (0.20 mmol), 5 Å MS (160 mg), solvent (1.5 mL) at 30 °C for 48 h, in CO, isolated yield. ^b Hantzsch ester (0.12 mmol).					

3. Synthetic application

3.1 Derivatization of 3ad




A dried 25 mL Schlenk tube was charged with **3ad** (0.10 mmol, 38.4 mg), PhB(OH)₂ (0.15 mmol, 18.3 mg), Pd(OAc)₂ (0.01 mmol, 2.3 mg) and PPh₃ (0.02 mmol, 5.3 mg), K₃PO₄ (0.25 mmol, 53.1 mg), 1.5 mL of toluene added by syringe. The reaction tube was vacuumed and refilled with N₂ for 3 times, and was placed in 70 °C oil-bath for 12 h. The crude reaction mixture was concentrated in vacuo and the residue was purified by silica gel flash column chromatography to afford the corresponding products **7**.

3.2 Stability on racemization of product 3aa

We investigated the racemization temperature of this axially chiral (*Ra*)-5-Chloro-2-(2-methyl-4-oxoquinazolin-3(4*H*)-yl)isoindoline-1,3-dione **3aa** scaffold.

Table S2: stability on racemization of product **3aa**



Entry	T / (°C)	Time (h)	ee of recovered 3aa (%)
1	90	12	81
2	100	12	81
3	110	12	79
4	120	12	77
5	130	12	75
6	140	12	67
7	150	12	65

4. DFT (density functional theory) calculations

4.1 Rotational Energy Barriers of Compound 3aa

DFT calculations were performed using ORCA 5.0.1 packages.¹ Equilibrium structures and transition states were fully optimized using M06-2X² density functional method with the def2-SVP basis sets,³ while single point energies were computed at RI-PWPB95(D3BJ)/def2TZVPP level⁴ with the SMD solvation model.⁵ Frequency analyses at 298 K were performed on M06-2X/def2-SVP optimized geometries to obtain thermodynamic corrections and to confirm the nature of the stationary points as equilibrium structures (with all real frequencies) or transition states (with only one imaginary frequency), and relative free energies, ΔG_{298} , were reported in these cases. Saddle points were connected to minima in the usual way with intrinsic reaction coordinate (IRC) calculations.⁶

Table S3. Zero-point energies (*ZPE*), enthalpy corrections (ΔH), free energy corrections (ΔG) of stationary points computed at the M062X/def2-SVP level, with single point electronic energies (*E*), enthalpies (*H*) and free energies (*G*) computed at the RI-PWPB95(D3BJ)/def2TZVPP (SMD: toluene) // M062X/def2-SVP level. All numbers are in hartrees.

Structure						
e	<i>ZPE</i>	ΔH	ΔG	<i>E</i>	<i>H</i>	<i>G</i>
I-GS	0.246154	0.265580	0.200923	-1503.453910	-1503.434484	-1503.499141
I-TS	0.245285	0.263655	0.201645	-1503.397159	-1503.378789	-1503.440799

4.2 Cartesian Coordinates

1-GS			
C	5.32475641517340	-1.93678709995562	0.18984190641610
C	6.00417461288338	-0.74826426199650	-0.12783767029210
C	5.31030608918442	0.43105153058645	-0.34234372053338
C	3.90710625619017	0.45394848310265	-0.24426532448095
C	3.23632769773133	-0.74239169443671	0.07394094773820
C	3.94386008485068	-1.93307368756721	0.29026085407166
N	3.24179876876556	1.65025779340108	-0.46380562625367

C	1.96430394098850	1.67616093442545	-0.37309968014792
N	1.21863288126322	0.53997231452932	-0.06161806164242
C	1.77475302699981	-0.73826231011599	0.18107676643768
N	-0.13761157959771	0.61020686368091	0.02448754282264
C	-0.96449508593570	0.13246264646859	-1.01849463326077
C	-2.31284141027692	-0.01252466723513	-0.38844267496725
C	-2.20876313484441	0.28062654006924	0.96943276248851
C	-0.79245094301343	0.63090067095606	1.28092838710977
C	-3.51578922269978	-0.37155716326013	-0.97349083681430
C	-4.62833356288477	-0.42707854710601	-0.12776764619877
C	-4.53745779292266	-0.13627398678203	1.23928739124329
C	-3.31378118427973	0.22451445523921	1.80584976839929
O	1.05782082167605	-1.67221471587714	0.44154944251130
O	-0.26826607978192	0.89852311968810	2.31923649580576
O	-0.60836372945712	-0.07181972319413	-2.13893442351764
Cl	-6.16578697631044	-0.86730265662527	-0.79034574653314
C	1.19119589002825	2.93696206138301	-0.60174736913770
H	5.88484425024559	-2.85690623839134	0.35865373075466
H	7.09268146280129	-0.75415785020439	-0.20573145444700
H	5.81882319623121	1.36308697408151	-0.58884016300245
H	3.37724656371607	-2.83180050184829	0.53766446485282
H	-3.59384617227771	-0.60286946014619	-2.03598423734946
H	-5.43925328685040	-0.19384341717645	1.84904917602324
H	-3.22529858405846	0.45288648144667	2.86864633674517
H	0.61298243768554	3.20308909041639	0.29492423757253
H	1.90752232826408	3.73087118529234	-0.83201818680105
H	0.48831902051258	2.81113183715157	-1.43776175561265
1-TS			
C	-5.53820446094922	-1.39868726251899	0.61208872006047
C	-5.89987307561236	-0.10727980226038	1.02639840536804
C	-5.05238552154402	0.97211798036442	0.82033082836210


C	-3.80106294035544	0.76762110091589	0.21915954960126
C	-3.43685520697697	-0.53263729328199	-0.16759538763697
C	-4.31122996009330	-1.61093391810011	-0.00081817205066
N	-2.98694523288872	1.83860448761488	-0.11124537612924
C	-1.76312897154366	1.63065308943995	-0.42552444192099
N	-1.21776337404346	0.32335146225402	-0.32624776658195
C	-2.10399430968801	-0.72178742776849	-0.76805434325279
N	0.15233469652364	0.08703496975593	-0.35582501913652
C	1.07983932826550	1.00979739181477	0.20318982515736
C	2.40223377208186	0.32014223114288	0.14844866432056
C	2.17404060854844	-1.02653236343680	-0.08659965666632
C	0.69892553015294	-1.23690442194979	-0.14511185421048
C	3.67097278081904	0.83100155777831	0.36163389106082
C	4.72373775478673	-0.08846064043013	0.30248089149296
C	4.50778743490452	-1.45216918328430	0.06735399405636
C	3.21314024625788	-1.94371173764138	-0.11613490413499
O	-1.76369100310151	-1.59825711073483	-1.50804841863805
O	0.10132942444219	-2.24067803350826	0.07621691295279
O	0.83528123273946	2.07708583692870	0.68343678423507
Cl	6.34410334974597	0.47270544334576	0.54219355589466
C	-1.00490590121235	2.73460776733714	-1.11435822857934
H	-6.22443216907811	-2.23166276006057	0.76840208206691
H	-6.86986842683189	0.05267938019155	1.50022017754279
H	-5.33424548478794	1.98828184885374	1.09674704232829
H	-3.99623263271959	-2.59912755656917	-0.33949339067900
H	3.84683791911303	1.88642389869280	0.56929568278449
H	5.36854186045960	-2.12057060689160	0.04271167737106
H	3.02451424292051	-3.00586401656997	-0.27514244196738
H	-0.14682136168023	2.35500264832059	-1.68093628816399
H	-1.71678918460386	3.20630809178097	-1.80224640436594
H	-0.65086096405064	3.48194994847446	-0.39756059054140

4.3 References:

- 1 (a) F. Neese, *WIREs Comput. Mol. Sci.*, 2012, **2**, 73-78; (b) F. Neese, *WIREs Comput. Mol. Sci.*, 2017, **8**, e1327; (c) F. Neese, F. Wennmohs, U. Becker and C. Riplinger, *J. Chem. Phys.*, 2020, **152**, 224108. (d) F. Neese, *WIREs Comput. Mol. Sci.*, 2022, **12**, e1606.
- 2 (a) T. Schwabe and S. Grimme, *Phys. Chem. Chem. Phys.*, 2007, **9**, 3397-3406; (b) T. Schwabe and S. Grimme, *Acc. Chem. Res.*, 2008, **41**, 569-579.
- 3 (a) F. Weigend and R. Ahlrichs, *Phys. Chem. Chem. Phys.*, 2005, **7**, 3297-3305; (b) F. Weigend, *Phys. Chem. Chem. Phys.*, 2006, **8**, 1057-1065.
- 4.(a) L. Goerigk and S. Grimme, *J. Chem. Theory Comput.*, 2011, **7**, 291–309; (b) A. Hellweg, C. Hattig, S. Hofener and W. Klopper. *Theory Chem. Acc.*, 2007, **117**, 587-597.
- 5 A. V. Marenich, C. J. Cramer and D. G. Truhlar, *J. Phys. Chem. B.*, 2009, **113**, 6378-6396.
- 6 (a) H. P. Hratchian and H. B. Schlegel, *J. Chem. Phys.*, 2004, **120**, 9918-9924; (b) H. P. Hratchian and H. B. Schlegel, *J. Chem. Theory Comput.*, 2005, **1**, 61-69.

5. Preparation of Starting Materials

5.1 Preparation of starting material with 3aa-3af and 3ak-3ar



(I) To a mixture of water and ethanol (100 mL) was added **A** (40 mmol). Subsequently, NaOH (120 mmol) was introduced, and the reaction was stirred at 60 °C for 5 h. After the reaction was completed, the reaction was extracted with ethyl acetate (3 times). The aqueous phase was collected, and an appropriate amount of HCl was added. The mixture was then extracted with ethyl acetate (20 mL $\times$ 3), and the organic layers were combined, the organic phase was dried over Na₂SO₄, filtered and concentrated in vacuo to afford yellow solid **B**.


(II) Compound **B** (20 mmol) was added to a 100 mL pear-shaped flask, followed by acetic anhydride (200 mmol). The mixture was refluxed for 5 hours. After the reaction was completed, the reaction was washed with sodium carbonate until the acetic anhydride was thoroughly removed. The solution was concentrated under vacuum and purified by column chromatography (silica gel, petroleum ether/EtOAc, 5:1) to yield white solid **C**.

(III) Compound **C** (10 mmol) was added to a 100 mL pear-shaped flask, followed by ethanol (20 mL) and hydrazine hydrate (11 mmol). The mixture was refluxed for 3 h. After the reaction was completed, the crude product was purified by silica gel flash column chromatography to afford (silica gel, petroleum ether/EtOAc, 5:1) to afford white solid **D**.

(IV) To a dry round-bottom flask equipped with a magnetic stir bar were added 2-

iodobenzoic acid with substituents (10 mmol) and thionyl chloride (10 mL). The mixture was refluxed at 80 °C for 30 minutes. After concentration under vacuum and further drying under high vacuum for 30 minutes, compound **D** (10 mmol) dissolved in pyridine was added under N₂. The mixture was refluxed at 115 °C for 30 minutes. Upon the reaction was completed, water was poured into the reaction mixture, and the solution was extracted with ethyl acetate (20 mL × 3), The organic phase was dried over Na₂SO₄, filtered and concentrated in vacuo. The crude product was purified by silica gel flash column chromatography to afford (silica gel, petroleum ether/ EtOAc, 5:1) the corresponding products **E** as a white solid.

5.2 Preparation of starting material with 3ag-3aj.




(I) Compound **A** (10 mmol) was added to a 100 mL Schlenk tube, followed by **B** (50 mmol) The mixture was refluxed for 8 h. After the reaction was completed, the crude product was purified by silica gel flash column chromatography to afford **C**.

(II) To a dry round-bottom flask equipped with a magnetic stir bar were added 5-chloro-2-iodobenzoic acid (10 mmol) and thionyl chloride (10 mL). The mixture was refluxed at 80 °C for 30 minutes. After concentration under vacuum and further drying under high vacuum for 30 minutes, compound **C** (5 mmol) dissolved in pyridine was added under N₂. The mixture was refluxed at 115 °C for 30 minutes. Upon the reaction was completed, water was poured into the reaction mixture, and the solution was extracted with ethyl acetate (20 mL × 3), The organic phase was dried over Na₂SO₄, filtered and concentrated in vacuo. The crude product was purified by silica gel flash column


chromatography to afford (silica gel, petroleum ether/ EtOAc, 5:1) the corresponding products **D** as a white solid.

5-Chloro-2-iodo-*N*-(2-methyl-4-oxoquinazolin-3(4*H*)-yl)benzamide (1a)




Flash column chromatography on silica gel (ethyl acetate/petroleum ether, 5:1) gave the product as a white solid (265 mg, 60% yield) : mp 235.3-237.1 °C; ¹H NMR (CDCl₃, 600 MHz) δ 9.52 (s, 1H), 7.91 (d, *J* = 7.8 Hz, 1H), 7.80-7.77 (m, 1H), 7.67 (d, *J* = 7.8 Hz, 1H), 7.50 (d, *J* = 8.4 Hz, 1H), 7.48 (d, *J* = 2.4 Hz, 1H), 7.43 (t, *J* = 7.2 Hz, 1H), 6.81 (dd, *J*₁ = 2.4 Hz, *J*₂ = 8.4 Hz, 1H), 2.76 (s, 3H); ¹³C NMR (150 MHz, CDCl₃) δ 163.0, 158.2, 153.8, 146.9, 142.4, 135.5, 135.5, 131.5, 128.0, 127.5, 127.4, 127.2, 126.0, 125.1, 120.5, 21.2.; MS (EI) 438 (M⁺); HRMS (ESI) *m/z* calcd for C₁₆H₁₂ClIN₃O₂⁺ (M+H)⁺ 439.9657, found 439.9651; IR: 3311, 3085, 2917, 1704, 773.

2-Iodo-5-methoxy-*N*-(2-methyl-4-oxoquinazolin-3(4*H*)-yl)benzamide (1b):




Flash column chromatography on silica gel (ethyl acetate/petroleum ether, 5:1) gave the product as a yellow solid (280 mg, 64% yield) : mp 202.1-205.3 °C; ¹H NMR (CDCl₃, 600 MHz) δ 8.89 (s, 1H), 8.05 (d, *J* = 7.8 Hz, 1H), 7.77 (t, *J* = 7.8 Hz, 1H), 7.68 (d, *J* = 8.4 Hz, 1H), 7.60 (d, *J* = 8.4 Hz, 1H), 7.43 (t, *J* = 7.2 Hz, 1H), 7.17 (d, *J* = 3.0 Hz, 1H), 6.58 (dd, *J*₁ = 8.4 Hz, *J*₂ = 3.0 Hz, 1H), 3.74 (s, 3H), 2.77 (s, 3H); ¹³C NMR (150 MHz, CDCl₃) δ 165.7, 164.3, 158.4, 154.2, 146.9, 135.4, 132.6, 127.5, 127.3, 127.1, 126.5, 121.7, 121.4, 120.6, 109.0, 56.3, 21.2.; MS (EI) 435 (M⁺); HRMS (ESI) *m/z* calcd for C₁₇H₁₅IN₃O₃⁺ (M+H)⁺ 436.0153, found 436.0153; IR: 3203, 3012, 2946, 1698, 1020


2-Iodo-5-methyl-*N*-(2-methyl-4-oxoquinazolin-3(4*H*)-yl)benzamide (1c):




Flash column chromatography on silica gel (ethyl acetate/petroleum ether, 5:1) gave the product as a yellow solid (315 mg, 75% yield) : mp 140.1-143.0 °C; ¹H NMR (DMSO-*d*₆, 600 MHz) δ 11.60 (s, 1H), 8.16 (d, *J* = 7.8 Hz, 1H), 7.88 (dd, *J*₁ = 16.2 Hz, *J*₂ = 7.8 Hz, 2H), 7.69 (d, *J* = 8.4 Hz, 1H), 7.58 (t, *J* = 7.2 Hz, 1H), 7.50 (s, 1H), 7.56 (d, *J* = 7.8 Hz, 1H), 2.60 (s, 3H), 2.37 (s, 3H); ¹³C NMR (150 MHz, CDCl₃) δ 164.4, 164.1, 158.3, 154.2, 147.1, 146.8, 135.9, 135.4, 130.2, 127.4, 127.4, 127.1, 125.0, 124.5, 120.5, 22.2, 21.1.; MS (EI) 419 (M⁺); HRMS (ESI) *m/z* calcd for C₁₇H₁₅IN₃O₂⁺ (M+H)⁺ 420.0203, found 420.0200; IR: 3473, 3133, 2919, 1700, 1384.

5-Bromo-2-iodo-N-(2-methyl-4-oxoquinazolin-3(4H)-yl)benzamide (1d):

Flash column chromatography on silica gel (ethyl acetate/petroleum ether, 5:1) gave the product as a white solid (300 mg, 62% yield) : mp 236.0-239.2°C; ¹H NMR (DMSO-*d*₆, 600 MHz) δ 11.78 (s, 1H), 8.16 (dd, *J*₁ = 7.8 Hz, *J*₂ = 1.2 Hz, 1H), 7.94 (d, *J* = 8.4 Hz, 1H), 7.90-7.87 (m, 1H), 7.77 (d, *J* = 2.4 Hz, 1H), 7.69 (d, *J* = 7.8 Hz, 1H), 7.58 (t, *J* = 7.8 Hz, 1H), 7.55 (dd, *J*₁ = 8.4 Hz, *J*₂ = 1.2 Hz, 1H), 2.59 (s, 3H); ¹³C NMR (150 MHz, DMSO-*d*₆) δ 166.9, 158.89, 155.8, 146.6, 141.7, 140.9, 135.3, 135.0, 131.2, 127.1, 126.9, 126.4, 121.3, 120.4, 92.5, 21.6; MS (EI) 482 (M⁺); HRMS (ESI) *m/z* calcd for C₁₆H₁₂BrIN₃O₂⁺ (M+H)⁺ 483.9152, found 483.9152; IR: 3309, 3077, 2979, 1700, 696.


2-Iodo-N-(2-methyl-4-oxoquinazolin-3(4H)-yl)-5-(trifluoromethyl)benzamide (1e):

Flash column chromatography on silica gel (ethyl acetate/petroleum ether, 5:1) gave the product as a white solid (350 mg, 74% yield) : mp 243.9-244.1 °C; ¹H NMR (DMSO-*d*₆, 600 MHz) δ 11.86 (s, 1H), 8.28 (d, *J* = 8.4 Hz, 1H), 8.17 (d, *J* = 8.4 Hz, 1H), 7.90 (d, *J* = 7.8 Hz, 1H), 7.88 (d, *J* = 6.6 Hz, 1H), 7.70 (d, *J* = 7.8 Hz, 2H), 7.58 (t, *J* = 7.2 Hz, 1H), 2.61 (s, 3H); ¹³C NMR (150 MHz, DMSO-*d*₆) δ 167.2, 158.9, 155.7, 146.6, 141.1, 140.2, 135.3, 128.7 (q, *J* = 31.5 Hz), 128.5 (q, *J* = 4.5 Hz), 127.0, 127.0, 126.5, 124.9 (q, *J* = 3.0 Hz), 123.7 (q, *J* = 271.5 Hz), 120.5, 99.7, 21.6; MS (EI) 472 (M⁺); HRMS (ESI) *m/z* calcd for C₁₇H₁₂F₃IN₃O₂⁺ (M+H)⁺ 473.9921, found 473.9920; IR: 3307, 3068, 2973, 1698, 825.

5-Fluoro-2-iodo-N-(2-methyl-4-oxoquinazolin-3(4H)-yl)benzamide (1f):


Flash column chromatography on silica gel (ethyl acetate/petroleum ether, 5:1) gave the product as a white solid (247 mg, 58% yield) : mp 223.8-225.3 °C; ¹H NMR (DMSO-*d*₆, 600 MHz) δ 11.75 (s, 1H), 8.16 (d, *J* = 7.8 Hz, 1H), 8.04 (dd, *J*₁ = 9.0 Hz, *J*₂ = 5.4 Hz, 1H), 7.88 (t, *J* = 7.8 Hz, 1H), 7.69 (d, *J* = 8.4 Hz, 1H), 7.58 (t, *J* = 7.2 Hz, 1H), 7.48 (dd, *J*₁ = 8.4 Hz, *J*₂ = 3.0 Hz, 1H), 7.27 (td, *J*₁ = 9.0 Hz, *J*₂ = 3.0 Hz, 1H), 2.60 (s, 3H); ¹³C NMR (150 MHz, DMSO-*d*₆) δ 167.0, 161.3 (d, *J* = 246.0 Hz), 158.8, 155.8, 146.6, 141.8 (d, *J* = 27.5 Hz), 140.7 (d, *J* = 6.0 Hz), 135.2, 127.0, 127.0, 126.5, 120.5, 119.7 (d, *J* = 21 Hz), 116.4 (d, *J* = 24.0 Hz), 87.6 (d, *J* = 4.5 Hz), 21.5; MS (EI) 422 (M⁺); HRMS (ESI) *m/z* calcd for C₁₆H₁₂FIN₃O₂⁺ (M+H)⁺ 423.9953, found 423.9952; IR: 3316, 3056, 2964, 1704, 811.

Methyl 3-(5-chloro-2-iodobenzamido)-4-oxo-3,4-dihydroquinazoline-2-carboxylate (1g):




Flash column chromatography on silica gel (ethyl acetate/petroleum ether, 5:1) gave the product as a white solid (215 mg, 44% yield) : mp 213.6-216.3 °C; ¹H NMR (DMSO-*d*₆, 600 MHz) δ 12.07 (s, 1H), 8.27 (d, *J* = 7.8 Hz, 1H), 8.01 (t, *J* = 9.0 Hz, 2H), 7.86 (d, *J* = 8.4 Hz, 1H), 7.75 (t, *J* = 7.8 Hz, 1H), 7.52 (d, *J* = 2.4 Hz, 1H), 7.43 (dd, *J*₁ = 2.4 Hz, *J*₂ = 8.4 Hz, 1H), 3.99 (s, 3H); ¹³C NMR (150 MHz, DMSO-*d*₆) δ 167.0, 160.0, 158.0, 147.3, 145.4, 141.7, 140.0, 135.9, 133.0, 132.2, 129.1, 128.6, 128.2, 126.9, 121.8, 91.8, 53.9; MS (EI) 482 (M⁺); HRMS (ESI) *m/z* calcd for C₁₈H₁₁ClIN₃O₄⁺ (M+H)⁺ 483.9556, found 483.9556; IR: 3272, 3081, 2852, 1712, 1305.

Ethyl 3-(5-chloro-2-iodobenzamido)-4-oxo-3,4-dihydroquinazoline-2-carboxylate (1h):



Flash column chromatography on silica gel (ethyl acetate/petroleum ether, 5:1) gave the product as a yellow solid (225 mg, 45% yield) : mp 235.0-235.9 °C; ¹H NMR (DMSO-*d*₆, 600 MHz) δ 2.06 (s, 1H), 8.27 (d, *J* = 7.8 Hz, 1H), 8.03-7.99 (m, 2H), 7.87 (t, *J* = 8.4 Hz, 1H), 7.74 (t, *J* = 7.8 Hz, 1H), 7.52 (d, *J* = 3.0 Hz, 1H), 7.42 (dd, *J*₁ = 8.4 Hz, *J*₂ = 2.4 Hz, 1H), 4.49-4.41 (m, 2H), 1.33 (t, *J* = 7.2 Hz, 3H); ¹³C NMR (150 MHz, DMSO-*d*₆) δ 166.9, 159.6, 158.0, 147.5, 145.5, 141.8, 139.7, 135.9, 133.0, 132.3, 129.1, 128.6, 128.1, 126.8, 121.7, 91.8, 63.2, 13.9; MS (EI) 496 (M⁺); HRMS (ESI) *m/z* calcd for C₁₉H₁₄ClIN₃O₄⁺ (M+H)⁺ 497.9712, found 497.9712; IR: 3274, 3087, 2979, 1714, 1374.


Butyl 3-(5-chloro-2-iodobenzamido)-4-oxo-3,4-dihydroquinazoline-2-carboxylate (1i):



Flash column chromatography on silica gel (ethyl acetate/petroleum ether, 5:1) gave the product as a white solid (220 mg, 42% yield) : mp 172.2-173.7 °C; ¹H NMR (DMSO-*d*₆, 600 MHz) δ 12.05 (s, 1H), 8.27 (d, *J* = 7.8 Hz, 1H), 8.03 (d, *J* = 8.4 Hz, 1H), 8.00 (d, *J* = 7.8 Hz, 1H), 7.86 (d, *J* = 8.4 Hz, 1H), 7.74 (t, *J* = 7.8 Hz, 1H), 7.51 (d, *J* = 2.4 Hz, 1H), 7.43 (dd, *J*₁ = 2.4 Hz, *J*₂ = 8.4 Hz, 1H), 4.46-


4.42 (m, 1H), 4.39-4.35 (m, 1H), 1.71-1.66 (m, 2H), 1.40-1.34 (m, 2H), 0.87 (t, $J = 7.2$ Hz, 3H); ^{13}C NMR (150 MHz, DMSO- d_6) δ 166.9, 159.7, 157.9, 147.6, 145.5, 141.9, 139.6, 135.9, 132.9, 132.4, 129.1, 128.6, 128.2, 126.8, 121.8, 91.9, 66.7, 29.9, 18.4, 13.5; MS (EI) 524 (M^+); HRMS (ESI) m/z calcd for $\text{C}_{20}\text{H}_{18}\text{ClIN}_3\text{O}_4^+$ ($\text{M}+\text{H}$) $^+$ 526.0025, found 526.0025; IR: 3247, 3087, 2956, 1716, 1467.

Benzyl 3-(5-chloro-2-iodobenzamido)-4-oxo-3,4-dihydroquinazoline-2-carboxylate (1j):




Flash column chromatography on silica gel (ethyl acetate/petroleum ether, 5:1) gave the product as a white solid (225 mg, 40% yield) : mp 207.1-209.7 °C; ^1H NMR (DMSO- d_6 , 600 MHz) δ 12.05 (s, 1H), 8.26 (d, $J = 8.4$ Hz, 1H), 8.01 (d, $J = 7.8$ Hz, 1H), 7.99 (d, $J = 7.2$ Hz, 1H), 7.87 (d, $J = 8.4$ Hz, 1H), 7.74 (t, $J = 7.2$ Hz, 1H), 7.47 (d, $J = 7.8$ Hz, 2H), 7.47-7.33 (m, 5H), 5.52-5.43 (m, 2H); ^{13}C NMR (150 MHz, DMSO- d_6) δ 167.1, 159.4, 158.0, 147.3, 145.4, 141.8, 139.7, 135.9, 134.6, 133.0, 132.3, 129.1, 128.6, 128.5, 128.5, 128.2, 126.9, 121.7, 91.9, 68.4; MS (EI) 558 (M^+); HRMS (ESI) m/z calcd for $\text{C}_{23}\text{H}_{16}\text{ClIN}_3\text{O}_4^+$ ($\text{M}+\text{H}$) $^+$ 559.9869, found 559.9869; IR: 3199, 3072, 2962, 1704, 1376.

5-Chloro-N-(2-ethyl-4-oxoquinazolin-3(4H)-yl)-2-iodobenzamide (1k):




Flash column chromatography on silica gel (ethyl acetate/petroleum ether, 5:1) gave the product as a yellow solid (305 mg, 67% yield) : mp 237.5-240.3 °C; ^1H NMR (DMSO- d_6 , 600 MHz) δ 11.71 (s, 1H), 8.18 (dd, $J_1 = 8.4$ Hz, $J_2 = 1.8$ Hz, 1H), 8.03 (d, $J = 8.4$ Hz, 1H), 7.92-7.89 (m, 1H), 7.74 (d, $J = 8.4$ Hz, 1H), 7.67 ($J = 3$ Hz, 1H), 7.59 (t, $J = 7.8$ Hz, 1H), 7.44 (dd, $J_1 = 8.4$ Hz, 1H, $J_2 = 2.4$ Hz, 1H), 3.00-2.85 (m, 2H), 1.32 (t, $J = 7.2$ Hz, 3H); ^{13}C NMR (150 MHz, DMSO- d_6) δ 167.2, 159.0, 158.9, 146.5, 141.4, 140.9, 135.2, 133.1, 132.1, 128.6, 127.3, 126.9, 126.4, 120.4, 91.7, 26.6, 10.7; MS (EI) 452 (M^+); HRMS (ESI) m/z calcd for $\text{C}_{17}\text{H}_{14}\text{ClIN}_3\text{O}_2^+$ ($\text{M}+\text{H}$) $^+$ 453.9814, found 458.9812; IR: 3155, 2988, 2952, 1687, 1605, 1375, 1100.

4-Chloro-2-iodo-N-(2-methyl-4-oxoquinazolin-3(4H)-yl)benzamide (1l):




Flash column chromatography on silica gel (ethyl acetate/petroleum ether, 5:1) gave the product as a yellow solid (330 mg, 75% yield) : mp 220.9-223.7 °C; ^1H NMR (DMSO- d_6 , 600 MHz) δ 11.71 (s, 1H), 8.16 (d, J = 8.4 Hz, 1H), 8.11 (d, J = 2.4 Hz, 1H), 7.89 (t, J = 7.8 Hz, 1H), 7.73-7.66 (m, 3H), 7.57 (t, J = 7.2 Hz, 1H), 2.59 (s, 3H); ^{13}C NMR (150 MHz, DMSO- d_6) δ 167.4, 158.8, 155.8, 146.5, 138.7, 137.9, 135.8, 135.2, 130.1, 128.3, 127.0, 126.9, 126.4, 120.5, 94.7, 21.5; MS (EI) 438 (M^+); HRMS (ESI) m/z calcd for $\text{C}_{16}\text{H}_{12}\text{ClIN}_3\text{O}_2^+$ ($\text{M}+\text{H}$) $^+$ 439.9657, found 439.9654; IR: 3318, 3083, 2969, 1698, 775.

2-Iodo-*N*-(2-methyl-4-oxoquinazolin-3(4*H*)-yl)-4-(trifluoromethyl)benzamide (1m):




Flash column chromatography on silica gel (ethyl acetate/petroleum ether, 5:1) gave the product as a yellow solid (206 mg, 63% yield) : mp 250.4-252.0 °C; ^1H NMR (DMSO- d_6 , 600 MHz) δ 11.83 (s, 1H), 8.34 (s, 1H), 8.16 (d, J = 7.8 Hz, 1H), 8.02 (d, J = 7.8 Hz, 1H), 7.89 (t, J = 7.8 Hz, 1H), 7.84 (d, J = 7.8 Hz, 1H), 7.70 (d, J = 7.8 Hz, 1H), 7.58 (t, J = 7.8 Hz, 1H), 2.62 (s, 3H); ^{13}C NMR (150 MHz, DMSO- d_6) δ 167.4, 158.8, 155.7, 146.6, 143.3, 135.9 (q, J = 4.5 Hz), 135.2, 131.8 (q, J = 31.5 Hz), 129.6, 127.0, 127.0, 126.5, 125.3 (q, J = 4.5 Hz), 122.7 (q, J = 270.0 Hz), 120.5, 94.3, 21.6; MS (EI) 472 (M^+); HRMS (ESI) m/z calcd for $\text{C}_{17}\text{H}_{12}\text{F}_3\text{IN}_3\text{O}_2^+$ ($\text{M}+\text{H}$) $^+$ 473.9921, found 473.9919; IR: 3241, 3093, 2983, 1710, 690.

4-Fluoro-2-iodo-*N*-(2-methyl-4-oxoquinazolin-3(4*H*)-yl)benzamide (1n):




Flash column chromatography on silica gel (ethyl acetate/petroleum ether, 5:1) gave the product as a yellow solid (275 mg, 65% yield) : mp 219.2-220.9 °C; ^1H NMR (DMSO- d_6 , 600 MHz) δ 11.66 (s, 1H), 8.16 (d, J = 7.8 Hz, 1H), 7.93 (dd, J_1 = 8.4 Hz, J_2 = 2.4 Hz, 1H), 7.90-7.87 (m, 1H), 7.73-7.71 (m, 1H), 7.69 (d, J = 8.4 Hz, 1H), 7.57 (t, J = 7.8 Hz, 1H), 7.50 (td, J_1 = 8.4 Hz, J_2 = 2.4 Hz, 1H), 2.59 (s, 3H); ^{13}C NMR (150 MHz, DMSO- d_6) δ 167.5, 162.4 (d, J = 252.0 Hz), 158.8, 155.9, 146.6, 135.6 (d, J = 3.0 Hz), 135.2, 130.7 (d, J = 9.0 Hz), 127.0, 126.9, 126.7 (d, J = 24.0 Hz), 126.5, 120.6, 115.4 (d, J = 21.0 Hz), 94.5 (d, J = 9.0 Hz), 21.6; MS (EI) 422 (M^+); HRMS (ESI) m/z calcd for $\text{C}_{16}\text{H}_{12}\text{FIN}_3\text{O}_2^+$ ($\text{M}+\text{H}$) $^+$ 423.9953, found 423.9953; IR: 3502, 3068, 2817, 1685, 863.

2-Iodo-4-methoxy-*N*-(2-methyl-4-oxoquinazolin-3(4*H*)-yl)benzamide (1o):




Flash column chromatography on silica gel (ethyl acetate/petroleum ether, 5:1) gave the product as a white solid (220 mg, 50% yield) : mp 191.3-193.0 °C; ^1H NMR (CDCl_3 , 600 MHz) δ 9.28 (s, 1H), 7.95 (dd, $J_1 = 1.2$ Hz, $J_2 = 7.8$ Hz, 1H), 7.74-7.72 (m, 1H), 7.63 (d, $J = 8.4$ Hz, 1H), 7.50 (d, $J = 8.4$ Hz, 1H), 7.38 (t, $J = 7.8$ Hz, 1H), 7.20 (d, $J = 2.4$ Hz, 1H), 6.69 (dd, $J_1 = 2.4$ Hz, $J_2 = 8.4$ Hz, 1H), 3.70 (s, 3H), 2.70 (s, 3H); ^{13}C NMR (150 MHz, CDCl_3) δ 168.9, 161.3, 160.6, 155.5, 147.0, 135.0, 130.3, 129.8, 127.1, 126.9, 126.5, 125.8, 120.5, 113.6, 93.1, 55.5, 22.0; MS (EI) 435 (M^+); HRMS (ESI) m/z calcd for $\text{C}_{17}\text{H}_{15}\text{IN}_3\text{O}_3^+$ ($\text{M}+\text{H}$) $^+$ 436.0153, found 436.0153; IR: 3203, 3012, 2946, 1698, 1020.

4-Bromo-2-iodo-*N*-(2-methyl-4-oxoquinazolin-3(4*H*)-yl)benzamide (1p):




Flash column chromatography on silica gel (ethyl acetate/petroleum ether, 5:1) gave the product as a yellow solid (290 mg, 60% yield) : mp 266.8-269.1 °C; ^1H NMR ($\text{DMSO}-d_6$, 600 MHz) δ 11.71 (s, 1H), 8.23 (s, 1H), 8.15 (d, $J = 7.8$ Hz, 1H), 7.89 (t, $J = 7.8$ Hz, 1H), 7.84 (dd, $J_1 = 8.4$ Hz, $J_2 = 1.8$ Hz, 1H), 7.69 (d, $J = 7.8$ Hz, 1H), 7.60-7.56 (m, 2H), 2.59 (s, 3H); ^{13}C NMR (150 MHz, $\text{DMSO}-d_6$) δ 167.5, 158.8, 155.8, 146.5, 141.3, 138.3, 135.2, 131.2, 130.4, 127.0, 126.9, 126.5, 124.5, 120.5, 95.9, 21.5; MS (EI) 482 (M^+); HRMS (ESI) m/z calcd for $\text{C}_{16}\text{H}_{12}\text{BrIN}_3\text{O}_2^+$ ($\text{M}+\text{H}$) $^+$ 483.9152, found 483.9151; IR: 3320, 3085, 2904, 1700, 694.

3-Fluoro-2-iodo-*N*-(2-methyl-4-oxoquinazolin-3(4*H*)-yl)benzamide (1q):




Flash column chromatography on silica gel (ethyl acetate/petroleum ether, 5:1) gave the product as a yellow solid (260 mg, 61% yield) : mp 131.6-132.3 °C; ^1H NMR ($\text{DMSO}-d_6$, 600 MHz) δ 11.73 (s, 1H), 8.16 (d, $J = 7.8$ Hz, 1H), 7.89 (t, $J = 7.8$ Hz, 1H), 7.70 (d, $J = 8.4$ Hz, 1H), 7.65-7.61 (m, 1H), 7.58 (t, $J = 7.2$ Hz, 1H), 7.50 (d, $J = 7.2$ Hz, 1H), 7.47 (t, $J = 8.4$ Hz, 1H), 2.57 (s, 3H); ^{13}C NMR (150 MHz, $\text{DMSO}-d_6$) δ 167.2, 161.5 (d, $J = 241.5$ Hz), 158.8, 155.8, 146.6, 141.4, 135.2, 130.8 (d, $J = 9.0$ Hz), 127.0, 127.0, 125.0 (d, $J = 4.5$ Hz), 120.6, 117.5 (d, $J = 24.0$ Hz), 82.6, 82.5 (d, $J = 28.5$ Hz), 21.6; MS (EI) 422 (M^+); HRMS (ESI) m/z calcd for $\text{C}_{16}\text{H}_{12}\text{FIN}_3\text{O}_2^+$ ($\text{M}+\text{H}$) $^+$ 423.9953, found 423.9953; IR: 3459, 3158, 2935, 1664, 848.

2-Iodo-4-methyl-N-(2-methyl-4-oxoquinazolin-3(4*H*)-yl)benzamide (1r):



Flash column chromatography on silica gel (ethyl acetate/petroleum ether, 5:1) gave the product as a yellow solid (288 mg, 69% yield) : mp 203.2-205.2 °C; ¹H NMR (DMSO-*d*₆, 600 MHz) δ 11.55 (s, 1H), 8.16 (d, *J* = 7.8 Hz, 1H), 7.58-7.55 (m, 2H), 7.69 (d, *J* = 7.8 Hz, 1H), 7.57 (t, *J* = 7.8 Hz, 2H), 7.43 (d, *J* = 7.8 Hz, 1H), 2.58 (s, 3H), 2.35 (s, 3H); ¹³C NMR (150 MHz, DMSO-*d*₆) δ 167.9, 158.9, 156.0, 146.6, 142.5, 141.0, 136.1, 135.1, 128.8, 128.7, 127.0, 126.9, 126.5, 120.6, 93.5, 21.5, 20.2; MS (EI) 419 (M⁺); HRMS (ESI) *m/z* calcd for C₁₇H₁₅IN₃O₂⁺ (M+H)⁺ 420.0203, found 420.0201; IR: 3183, 3004, 2927, 1720, 1376.


2-Iodo-3-methyl-N-(2-methyl-4-oxoquinazolin-3(4*H*)-yl) benzamide (1s):




Flash column chromatography on silica gel (ethyl acetate/petroleum ether, 5:1) gave the product as a yellow solid (210 mg, 50 % yield) : mp 120.1-128.6 °C; ¹H NMR (DMSO-*d*₆, 600 MHz), δ 11.58 (s, 1H), 8.16 (dd, *J*₁ = 8.4 Hz, *J*₂ = 1.8 Hz, 1H), 7.90-7.87 (m, 1H), 7.69 (d, *J* = 7.8 Hz, 1H), 7.59-7.56 (m, 1H), 7.52-7.50 (m, 1H), 7.48 (d, *J* = 7.8 Hz, 1H), 7.44 (dd, *J*₁ = 7.2 Hz, *J*₂ = 2.4 Hz, 1H), 2.62 (s, 3H), 2.48 (s, 3H); ¹³C NMR (150 MHz, DMSO-*d*₆) δ 168.7, 158.9, 156.0, 146.6, 142.6, 140.8, 135.1, 131.4, 128.3, 127.0, 126.9, 126.5, 126.2, 120.6, 99.7, 28.5, 21.7; MS (EI) 419 (M⁺); HRMS (ESI) *m/z* calcd for C₁₇H₁₅IN₃O₂⁺ (M+H)⁺ 420.0203, found 420.0202; IR: 3455, 3156, 2910, 1622, 1380.

6. Characterization Data for the Products


(*Ra*)-5-Chloro-2-(2-methyl-4-oxoquinazolin-3(4*H*)-yl)isoindoline-1,3-dione (3aa):




Flash column chromatography on silica gel (ethyl acetate/petroleum ether, 1:2) gave the product (26.21 mg, 77% yield) as a yellow solid: mp 203.6-205.1 °C; $[\alpha]_D^{25} = -13.60$ ($c = 0.10$ in MeCN, 81% ee); ^1H NMR (CDCl_3 , 600 MHz) δ 8.22 (d, $J = 8.4$ Hz, 1H), 7.80 (d, $J = 1.8$ Hz, 1H), 7.96 (d, $J = 7.8$ Hz, 1H), 7.86 (dd, $J_1 = 7.8$ Hz, $J_2 = 1.8$ Hz, 1H), 7.83-7.80 (m, 1H), 7.72 (d, $J = 8.4$ Hz, 1H), 7.50 (t, $J = 7.2$ Hz, 1H), 2.49 (s, 3H); ^{13}C NMR (150 MHz, CDCl_3) δ 163.3, 163.0, 158.2, 153.8, 146.9, 142.4, 135.5, 135.5, 131.5, 127.9, 127.5, 127.4, 127.2, 126.0, 125.1, 120.5, 21.2; MS (EI) 339 (M^+); HRMS (ESI) m/z calcd for $\text{C}_{17}\text{H}_{11}\text{ClN}_3\text{O}_3^+$ ($\text{M}+\text{H}$) $^+$ 340.0483, found 340.0483. The enantiomeric ratio was determined by Daicel Chiralcel AD-H (0.46 cm $\times$ 25 cm), Hexanes/IPA = 80/20, 1.0 mL/min, $\lambda = 254$ nm, t (minor) = 19.3 min, t (major) = 20.8 min; IR: 3095, 2925, 1747, 1698, 730.



(*Ra*)-5-Methoxy-2-(2-methyl-4-oxoquinazolin-3(4*H*)-yl)isoindoline-1,3-dione (3ab):




Flash column chromatography on silica gel (ethyl acetate/petroleum ether, 1:2) gave the product (19.5 mg, 56% yield) as a yellow solid: mp 188.3-190.7 °C; $[\alpha]_D^{25} = -5.60$ ($c = 0.10$ in MeCN, 71% ee); ^1H NMR (CDCl_3 , 600 MHz) δ 8.22 (d, $J = 7.8$ Hz, 1H), 7.92 (d, $J = 8.4$ Hz, 1H), 7.81-7.79 (m, 1H), 7.71 (d, $J = 8.4$ Hz, 1H), 7.49 (d, $J = 7.8$ Hz, 1H), 7.47 (d, $J = 2.4$ Hz, 1H), 7.32 (dd, $J_1 = 8.4$ Hz, $J_2 = 2.4$ Hz, 1H), 3.98 (s, 3H), 2.49 (s, 3H); ^{13}C NMR (150 MHz, CDCl_3) δ 164.4, 164.1, 158.3, 154.2, 147.1, 146.9, 135.9, 135.3, 130.2, 127.4, 127.3, 127.3, 127.1, 125.1, 124.5, 120.6, 22.2, 21.2; MS (EI) 335 (M^+); HRMS (ESI) m/z calcd for $\text{C}_{18}\text{H}_{14}\text{ClN}_3\text{O}_4^+$ ($\text{M}+\text{H}$) $^+$ 336.0979, found 336.0979. The enantiomeric ratio was determined by Daicel Chiralcel AD-H (0.46 cm $\times$ 25 cm), Hexanes/IPA = 80/20, 1.0 mL/min, $\lambda = 254$ nm, t (minor) = 31.7 min, t (major) = 48.8 min; IR: 3012, 2925, 1749, 1698, 1089.




NO.	Ret-Time	Area(uAU*min)	Height(uAU)	Potency	Rel.-Area-%
1	31.393	1552507	25627	49.115	49.115
2	48.627	1608462	16247	50.885	50.885
Total		3160969	41874	100.000	100.000

NO.	Ret-Time	Area(uAU*min)	Height(uAU)	Potency	Rel.-Area-%
1	31.755	2900102	49332	14.721	14.721
2	48.798	16800766	170132	85.279	85.279
Total		19700868	219464	100.000	100.000

(*Ra*)-5-Methyl-2-(2-methyl-4-oxoquinazolin-3(4*H*)-yl)isoindoline-1,3-dione (3ac):




Flash column chromatography on silica gel (ethyl acetate/petroleum ether, 1:2) gave the product (27.9 mg, 87% yield) as a yellow solid: mp 164.4-165.9 °C; $[\alpha]_D^{25} = 55.60$ ($c = 0.10$ in MeCN, 79% ee); ^1H NMR (CDCl_3 , 600 MHz) δ 8.21 (d, $J = 7.8$ Hz, 1H), 7.89 (d, $J = 7.8$ Hz, 1H), 7.81 (s, 1H), 7.80 (d, $J = 8.4$ Hz, 1H), 7.71 (d, $J = 8.4$ Hz, 1H), 7.67 (d, $J = 7.8$ Hz, 1H), 7.48 (t, $J = 7.2$ Hz, 1H), 2.58 (s, 3H), 2.49 (s, 3H); ^{13}C NMR (150 MHz, CDCl_3) δ 164.4, 164.2, 158.3, 154.2, 147.1, 146.9, 136.0, 135.3, 130.3, 127.4, 127.4, 127.1, 125.1, 124.6, 120.6, 22.2, 21.2; MS (EI) 319 (M^+); HRMS (ESI) m/z calcd for $\text{C}_{18}\text{H}_{14}\text{N}_3\text{O}_3^+$ ($M+H$) $^+$ 320.1030, found 320.1029. The enantiomeric ratio was determined by Daicel Chiralcel AD-H (0.46 cm $\times$ 25 cm), Hexanes/IPA = 80/20, 1.0 mL/min, $\lambda = 254$ nm, t (minor) = 15.9 min, t (major) = 21.5 min; IR: 3014, 2927, 1749, 1704, 1384.



NO.	Ret-Time	Area(uAU*min)	Height(uAU)	Potency	Rel.-Area-%
1	15.964	940511	43284	50.015	50.015
2	21.601	939965	33301	49.985	49.985
Total		1880476	76585	100.000	100.000


NO.	Ret-Time	Area(uAU*min)	Height(uAU)	Potency	Rel.-Area-%
1	15.880	1807130	85015	10.692	10.692
2	21.534	1509404	529404	89.308	89.308
Total		16902085	614419	100.000	100.000

(*Ra*)-5-Bromo-2-(2-methyl-4-oxoquinazolin-3(4*H*)-yl)isoindoline-1,3-dione (3ad):




Flash column chromatography on silica gel (ethyl acetate/petroleum ether, 1:2) gave the product (28.9 mg, 75% yield) as a yellow solid: mp 189.3-190.7 °C; $[\alpha]_D^{25} = -141.0$ ($c = 0.20$ in MeCN, 81% ee); ^1H NMR (CDCl_3 , 600 MHz) δ 8.21 (d, $J = 8.4$ Hz, 1H), 8.15 (s, 1H), 8.03 (dd, $J_1 = 8.4$ Hz, $J_2 = 1.8$ Hz, 1H), 7.88 (d, $J = 7.8$ Hz, 1H), 7.82 (t, $J = 7.8$ Hz, 1H), 7.71 (d, $J = 8.4$ Hz, 1H), 7.50 (t, $J = 7.8$ Hz, 1H), 2.49 (s, 3H); ^{13}C NMR (150 MHz, CDCl_3) δ 163.4, 163.0, 158.2, 153.7, 146.8, 138.4,


135.5, 131.5, 130.6, 128.3, 128.0, 127.5, 127.4, 127.3, 125.9, 120.5, 21.1; MS (EI) 382 (M^+); HRMS (ESI) m/z calcd for $C_{17}H_{11}FN_3O_3^+$ ($M+H$) $^+$ 383.9978, found 383.9977. The enantiomeric ratio was determined by Daicel Chiralcel AD-H (0.46 cm $\times$ 25 cm), Hexanes/IPA = 80/20, 1.0 mL/min, λ = 254 nm, t (minor) = 32.3 min, t (major) = 35.4 min; IR: 3062, 2929, 1749, 1697, 692.




(*Ra*)-2-(2-Methyl-4-oxoquinazolin-3(4*H*)-yl)-5-(trifluoromethyl)isoindoline-1,3-dione (3ae):




Flash column chromatography on silica gel (ethyl acetate/petroleum ether, 1:2) gave the product (10.3 mg, 28% yield) as a yellow solid: mp 80.2-83.2 °C; $[\alpha]_D^{25}$ = -35.4 (c = 0.10 in MeCN, 57% ee); 1H NMR ($CDCl_3$, 600 MHz) δ 8.29 (s, 1H), 8.22 (d, J = 8.4 Hz, 1H), 8.18 (s, 2H), 7.83 (t, J = 7.8 Hz, 1H), 7.73 (d, J = 8.4 Hz, 1H), 7.52 (t, J = 7.8 Hz, 1H), 2.50 (s, 3H); ^{13}C NMR (150 MHz, $CDCl_3$) δ 162.9, 162.8, 158.1, 153.5, 146.8, 137.5 (q, J = 34.5 Hz), 135.6, 132.7, 132.5 (q, J = 3.0 Hz), 130.7, 127.6, 127.4, 127.4, 125.3, 122.7 (q, J = 271.5 Hz), 121.9 (q, J = 4.5 Hz), 120.4, 21.2; MS (EI) 373 (M^+); HRMS (ESI) m/z calcd for $C_{18}H_{11}F_3N_3O_3^+$ ($M+H$) $^+$ 374.0747, found 374.0747. The enantiomeric ratio was determined by Daicel Chiralcel AD-H (0.46 cm $\times$ 25 cm), Hexanes/IPA = 90/10, 1.0 mL/min, λ = 254 nm, t (minor) = 14.2 min, t (major) = 17.0 min; IR: 3089, 2925, 1702, 771.




(*Ra*)-5-Fluoro-2-(2-methyl-4-oxoquinazolin-3(4*H*)-yl)isoindoline-1,3-dione (3af):



Flash column chromatography on silica gel (ethyl acetate/petroleum ether, 1:2) gave the product (22.5 mg, 70% yield) as a yellow solid: mp 190.2-195.7 °C; $[\alpha]_D^{25} = -68.30$ ($c = 0.20$ in MeCN, 79% ee); ^1H NMR (CDCl_3 , 600 MHz) δ 8.29 (s, 1H), 8.22 (dd, $J_1 = 7.8$ Hz, $J_2 = 1.2$ Hz, 1H), 8.17 (d, $J = 1.2$ Hz, 2H), 7.84-7.82 (m, 1H), 7.72 (d, $J = 8.4$ Hz, 1H), 7.51 (t, $J = 7.8$ Hz, 1H), 2.49 (s, 3H); ^{13}C NMR (150 MHz, CDCl_3) δ 167.0 (d, $J = 258.0$ Hz), 163.1, 163.0, 163.0, 158.2, 153.9, 146.9, 135.4, 132.7 (d, $J = 10.5$ Hz), 127.5, 127.4 (d, $J = 4.5$ Hz), 127.3 (d, $J = 4.5$ Hz), 125.8 (d, $J = 3.0$ Hz), 125.1 (d, $J = 24.0$ Hz), 120.5, 112.5 (d, $J = 25.5$ Hz), 21.1; MS (EI) 323 (M^+); HRMS (ESI) m/z calcd for $\text{C}_{17}\text{H}_{11}\text{FN}_3\text{O}_3^+$ ($\text{M}+\text{H}^+$) 324.0779, found 324.0778. The enantiomeric ratio was determined by Daicel Chiralcel AD-H (0.46 cm $\times$ 25 cm), Hexanes/IPA = 80/20, 1.0 mL/min, $\lambda = 254$ nm, t (minor) = 31.4 min, t (major) = 35.1 min; IR: 3073, 2919, 1752, 1702, 927.




(*Ra*)-Methyl 3-(5-chloro-1,3-dioxisoindolin-2-yl)-4-oxo-3,4-dihydroquinazoline-2-carboxylate (3ag):




Flash column chromatography on silica gel (ethyl acetate/petroleum ether, 1:2) gave the product (17.0 mg, 45% yield) as a yellow solid: mp 186.2-189.1 °C; $[\alpha]_D^{25} = 4.20$ ($c = 0.10$ in MeCN, 69% ee); ^1H NMR (CDCl_3 , 600 MHz) δ 8.21 (dd, $J_1 = 7.8$ Hz, $J_2 = 1.2$ Hz, 1H), 7.99 (d, $J = 2.4$ Hz, 1H), 7.96 (d, $J = 8.4$ Hz, 1H), 7.85 (dd, $J_1 = 7.8$ Hz, $J_2 = 1.8$ Hz, 1H), 7.83-7.80 (m, 1H), 7.71 (d, $J = 8.4$ Hz, 1H), 7.49 (t, $J = 7.8$ Hz, 1H), 2.49 (s, 3H); ^{13}C NMR (150 MHz, CDCl_3) δ 163.3, 163.0, 158.1, 153.8, 146.8, 142.4, 138.4, 135.6, 135.4, 131.5, 127.9, 127.5, 127.4, 127.3, 125.9, 125.0, 120.5, 21.2; MS (EI) 383 (M^+); HRMS (ESI) m/z calcd for $\text{C}_{18}\text{H}_{11}\text{ClN}_3\text{O}_5^+$ ($\text{M}+\text{H}^+$) 384.0382, found 384.0382. The enantiomeric ratio was determined by Daicel Chiralcel AD-H (0.46 cm $\times$ 25 cm), Hexanes/IPA = 80/20, 1.0 mL/min, $\lambda = 254$ nm, t (minor) = 22.2 min, t (major) = 31.9 min; IR: 3100, 2925, 1712, 1211, 1380.




(*Ra*)-Ethyl-3-(5-chloro-1,3-dioxoisindolin-2-yl)-4-oxo-3,4-dihydroquinazoline-2-carboxylate (3ah):




Flash column chromatography on silica gel (ethyl acetate/petroleum ether, 1:2) gave the product (26.5 mg, 67% yield) as a yellow solid: mp 189.5-192.0 °C; $[\alpha]_D^{25} = 13.60$ ($c = 0.20$ in MeCN, 71% ee); ^1H NMR (DMSO- d_6 , 600 MHz) δ 8.31 (d, $J = 1.8$ Hz, 1H), 8.26 (d, $J = 7.8$ Hz, 1H), 8.18 (d, $J = 8.4$ Hz, 1H), 8.14 (dd, $J_1 = 7.8$ Hz, $J_2 = 1.8$ Hz, 1H), 8.10 (t, $J = 7.2$ Hz, 1H), 7.98 (d, $J = 8.4$ Hz, 1H), 7.82 (t, $J = 7.8$ Hz, 1H), 4.31 (q, $J = 7.2$ Hz, 2H), 1.15 (t, $J = 7.2$ Hz, 3H); ^{13}C NMR (150 MHz, DMSO- d_6) δ 162.5, 162.1, 158.4, 157.0, 144.8, 144.0, 141.5, 137.0, 136.3, 130.6, 130.4, 128.9, 127.3, 127.3, 126.8, 125.2, 120.8, 63.6, 13.5; MS (EI) 397 (M^+); HRMS (ESI) m/z calcd for $\text{C}_{19}\text{H}_{13}\text{ClN}_3\text{O}_5^+$ ($M+H$) $^+$ 398.0538, found 398.0535. The enantiomeric ratio was determined by Daicel Chiralcel AD-H (0.46 cm $\times$ 25 cm), Hexanes/IPA = 80/20, 1.0 mL/min, $\lambda = 254$ nm, t (minor) = 25.1 min, t (major) = 28.6 min; IR: 3075, 2927, 1749, 1716, 1338, 1267.




(Ra)-Butyl 3-(5-chloro-1,3-dioxoisindolin-2-yl)-4-oxo-3,4-dihydroquinazoline-2-carboxylate (3ai):



Flash column chromatography on silica gel (ethyl acetate/petroleum ether, 1:2) gave the product (31.4 mg, 74% yield) as a yellow solid: mp 189.6-193.6 °C; $[\alpha]_D^{25} = 12.20$ ($c = 0.10$ in MeCN, 73% ee); ^1H NMR (DMSO- d_6 , 600 MHz) δ 8.31 (d, $J = 1.8$ Hz, 1H), 8.26 (d, $J = 8.4$ Hz, 1H), 8.19 (d, $J = 8.4$ Hz, 1H), 8.14 (dd, $J_1 = 7.8$ Hz, $J_2 = 1.8$ Hz, 1H), 8.09 (t, $J = 8.4$ Hz, 1H), 7.97 (d, $J = 7.8$ Hz, 1H), 7.81 (t, $J = 7.8$ Hz, 1H), 4.28 (t, $J = 6.6$ Hz, 2H), 1.51-1.46 (m, 2H), 1.22 (q, $J = 7.2$ Hz, 2H), 0.76 (t, $J = 7.8$ Hz, 3H); ^{13}C NMR (150 MHz, DMSO- d_6) δ 162.5, 162.2, 158.5, 156.9, 144.9, 144.2, 141.6, 137.0, 136.4, 130.6, 130.3, 128.9, 127.2, 127.3, 126.7, 125.3, 120.8, 67.1, 29.7, 18.3, 13.3; MS (EI) 425 (M^+); HRMS (ESI) m/z calcd for $\text{C}_{21}\text{H}_{17}\text{ClN}_3\text{O}_5^+$ ($M+H$) $^+$ 426.0851, found 426.0851. The enantiomeric ratio was determined by Daicel Chiralcel AD-H (0.46 cm $\times$ 25 cm), Hexanes/IPA = 80/20, 1.0 mL/min, $\lambda = 254$ nm, t (minor) = 18.5 min, t (major) = 22.7 min; IR: 3102, 2964, 1751, 1714, 1467, 1261.




(Ra)-Benzyl 3-(5-chloro-1,3-dioxoisindolin-2-yl)-4-oxo-3,4-dihydroquinazoline-2-carboxylate (3aj):




Flash column chromatography on silica gel (ethyl acetate/petroleum ether, 1:2) gave the product (27.5 mg, 60% yield) as a yellow solid: mp 190.0-193.2 °C; $[\alpha]_D^{25} = 25.0$ ($c = 0.10$ in MeCN, 37% ee); ^1H NMR (CDCl_3 , 600 MHz) δ 8.31 (d, $J = 6.0$ Hz, 1H), 7.94 (d, $J = 6.0$ Hz, 1H), 7.91-7.8 (m, 1H), 7.80-7.78 (m, 2H), 7.66-7.63 (m, 1H), 7.27-7.26 (m, 5H), 7.2-7.19 (m, 2H), 5.31 (dd, $J_1 = 6.0$ Hz, $J_2 = 12.0$ Hz, 2H); ^{13}C NMR (150 MHz, CDCl_3) δ 162.3, 162.0, 158.6, 157.6, 145.4, 143.7, 141.9, 135.8, 135.1, 133.9, 131.2, 129.6, 129.2, 128.8, 128.7, 128.5, 127.2, 127.6, 125.7, 124.9, 122.1, 68.9; MS (EI) 459 (M^+); HRMS (ESI) m/z calcd for $\text{C}_{24}\text{H}_{15}\text{ClN}_3\text{O}_5^+$ ($M+H$) $^+$ 460.0695, found 460.0693. The enantiomeric ratio was determined by Daicel Chiralcel AD-H (0.46 cm $\times$ 25 cm), Hexanes/IPA = 80/20, 1.0 mL/min, $\lambda = 254$ nm, t (minor) = 28.4 min, t (major) = 35.7 min; IR:


3081, 2929, 1754, 1700, 1259.




(*Ra*)-5-chloro-2-(2-ethyl-4-oxoquinazolin-3(4*H*)-yl)isoindoline-1,3-dione (3ak):




Flash column chromatography on silica gel (ethyl acetate/petroleum ether, 1:2) gave the product (19.2 mg, 54% yield) as a yellow solid: mp 195.3-198.4°C; $[\alpha]_D^{25} = 22.04$ ($c = 0.10$ in MeCN, 77% ee); ^1H NMR (DMSO- d_6 , 600 MHz) δ 8.27 (d, $J = 1.8$ Hz, 1H), 8.15 (d, $J = 8.4$ Hz, 1H), 8.13-8.12 (m, 2H), 8.12-8.10 (m, 1H), 7.79 (d, $J = 7.8$ Hz, 1H), 7.62 (t, $J = 7.8$ Hz, 1H), 2.79 (q, $J = 7.8$ Hz, 2H), 1.22 (t, $J = 7.8$ Hz, 3H); ^{13}C NMR (150 MHz, DMSO- d_6) δ 164.0, 163.8, 158.5, 158.1, 146.7, 141.5, 136.7, 136.4, 131.8, 128.4, 128.2, 127.2, 127.0, 125.3, 119.8, 26.3, 10.8; MS (EI) 353 (M^+); HRMS (ESI) m/z calcd for $\text{C}_{18}\text{H}_{13}\text{ClN}_3\text{O}_3^+$ ($M+H$) $^+$ 354.0640, found 354.0641. The enantiomeric ratio was determined by Daicel Chiralcel AD-H (0.46 cm $\times$ 25 cm), Hexanes/IPA = 80/20, 1.0 mL/min, $\lambda = 254$ nm, t (minor) = 12.2 min, t (major) = 15.1 min; IR: 3092, 3080, 2991, 2935, 1748, 1700, 1605, 1345, 1280.




(*Sa*)-4-Chloro-2-(2-methyl-4-oxoquinazolin-3(4*H*)-yl)isoindoline-1,3-dione (3al):




Flash column chromatography on silica gel (ethyl acetate/petroleum ether, 1:2) gave the product (21.9 mg, 64% yield) as a yellow solid: mp 192.5-197.4°C; $[\alpha]_D^{25} = -33.4$ ($c = 0.10$ in MeCN, 77% ee); ^1H NMR (CDCl_3 , 600 MHz) δ 8.20 (dd, $J_1 = 7.8$ Hz, $J_2 = 1.8$ Hz, 1H), 7.98 (d, $J = 1.8$ Hz, 1H), 7.95 (d, $J = 7.8$ Hz, 1H), 7.85 (dd, $J_1 = 7.8$ Hz, $J_2 = 1.8$ Hz, 1H), 7.83-7.80 (m, 1H), 7.71 (d, $J = 8.4$ Hz, 1H), 7.49 (t, $J = 7.8$ Hz, 1H), 2.49 (s, 3H); ^{13}C NMR (150 MHz, CDCl_3) δ 163.3, 163.0, 158.1, 153.7, 146.8, 142.3, 135.5, 135.5, 131.5, 127.9, 127.5, 127.4, 127.2, 125.9, 125.0, 120.4, 21.2; MS (EI) 339 (M^+); HRMS (ESI) m/z calcd for $\text{C}_{17}\text{H}_{11}\text{ClN}_3\text{O}_3^+$ ($\text{M}+\text{H}$) $^+$ 340.0483, found 340.0482. The enantiomeric ratio was determined by Daicel Chiralcel AD-H (0.46 cm $\times$ 25 cm), Hexanes/IPA = 80/20, 1.0 mL/min, $\lambda = 254$ nm, t (minor) = 19.2 min, t (major) = 20.8 min; IR: 3064, 2923, 1749, 1700, 779.




(Sa)-2-(2-Methyl-4-oxoquinazolin-3(4H)-yl)-4-(trifluoromethyl)isoindoline-1,3-dione (3am):




Flash column chromatography on silica gel (ethyl acetate/petroleum ether, 1:2) gave the product (17.7 mg, 47% yield) as a yellow solid: mp 116.1-119.8 °C; $[\alpha]_D^{25} = 5.20$ ($c = 0.20$ in MeCN, 61% ee); ^1H NMR (CDCl_3 , 600 MHz) δ 8.21 (dd, $J_1 = 7.8$ Hz, $J_2 = 1.2$ Hz, 1H), 8.03 (q, $J = 4.2$ Hz, 1H), 7.83-7.80 (m, 1H), 7.72 (d, $J = 7.8$ Hz, 1H), 7.70 (dd, $J_1 = 7.2$ Hz, $J_2 = 2.4$ Hz, 1H), 7.56 (td, $J_1 = 8.4$ Hz, $J_2 = 2.4$ Hz, 1H), 7.51-7.48 (m, 1H), 2.49 (s, 3H); ^{13}C NMR (150 MHz, CDCl_3) δ 162.9, 162.8, 158.1, 153.5, 146.8, 137.5 (q, $J = 34.5$ Hz), 135.6, 132.7, 132.5 (q, $J = 3.0$ Hz), 130.7, 127.6, 127.4, 127.4, 125.3, 122.7 (q, $J = 271$ Hz), 121.9 (q, $J = 3.0$ Hz), 120.4, 21.1; MS (EI) 373 (M^+); HRMS (ESI) m/z calcd for $\text{C}_{18}\text{H}_{11}\text{F}_3\text{N}_3\text{O}_3^+$ ($\text{M}+\text{H}$) $^+$ 374.0747, found 374.0745. The enantiomeric ratio was determined by Daicel Chiralcel AD-H (0.46 cm $\times$ 25 cm), Hexanes/IPA = 80/20, 1.0 mL/min, $\lambda = 254$ nm, t (minor) = 16.2 min, t (major) = 17.0 min; IR: 3083, 2929, 1731, 1679, 771.




(Sa)-4-Fluoro-2-(2-methyl-4-oxoquinazolin-3(4H)-yl)isoindoline-1,3-dione (3an):




Flash column chromatography on silica gel (ethyl acetate/petroleum ether, 1:2) gave the product (22.3 mg, 69% yield) as a yellow solid: mp 181.1-185.0 °C; $[\alpha]_D^{25} = -57.40$ ($c = 0.20$ in MeCN, 75% ee); ^1H NMR (CDCl_3 , 600 MHz) δ 8.21 (d, $J = 7.8$ Hz, 1H), 8.04 (dd, $J_1 = 7.8$ Hz, $J_2 = 4.2$ Hz, 1H), 7.83-7.80 (m, 1H), 7.72 (d, $J = 8.4$ Hz, 1H), 7.69 (dd, $J_1 = 6.6$ Hz, $J_2 = 2.4$ Hz, 1H), 7.56 (td, $J_1 = 9.0$ Hz, $J_2 = 2.4$ Hz, 1H), 7.50 (t, $J = 7.8$ Hz, 1H), 2.49 (s, 3H); ^{13}C NMR (150 MHz, CDCl_3) δ 166.7 (d, $J = 259.5$ Hz), 163.1, 163.0, 163.0, 158.2, 153.8, 146.9, 135.5, 132.8 (d, $J = 9.0$ Hz), 127.5, 127.3, (d, $J = 6.0$ Hz), 127.3 (d, $J = 3.0$ Hz), 125.8 (d, $J = 3.0$ Hz), 122.7 (d, $J = 24.0$ Hz), 120.4, 112.5 (d, $J = 25.5$ Hz), 21.1; MS (EI) 323 (M^+); HRMS (ESI) m/z calcd for $\text{C}_{17}\text{H}_{11}\text{FN}_3\text{O}_3^+$ ($\text{M}+\text{H}$) $^+$ 324.0779, found 324.0778. The enantiomeric ratio was determined by Daicel Chiralcel AD-H (0.46 cm $\times$ 25 cm), Hexanes/IPA = 80/20, 1.0 mL/min, $\lambda = 254$ nm, t (minor) = 31.5 min, t (major) = 34.8 min; IR: 3064, 2921, 1752, 1702, 925.




(Sa)-4-Methoxy-2-(2-methyl-4-oxoquinazolin-3(4H)-yl)isoindoline-1,3-dione (3ao):




Flash column chromatography on silica gel (ethyl acetate/petroleum ether, 1:2) gave the product (19.4 mg, 58% yield) as a yellow solid: mp 187.6-192.5 °C; $[\alpha]_D^{25} = -23.8$ (c = 0.10 in MeCN, 75% ee); ^1H NMR (CDCl_3 , 600 MHz) δ 8.21 (d, $J = 8.4$ Hz, 1H), 7.91 (d, $J = 8.4$ Hz, 1H), 7.80 (t, $J = 7.8$ Hz, 1H), 7.71 (d, $J = 8.4$ Hz, 1H), 7.49 (d, $J = 7.8$ Hz, 1H), 7.47 (d, $J = 2.4$ Hz, 1H), 7.32 (dd, $J_1 = 8.4$ Hz, $J_2 = 2.4$ Hz, 1H), 3.97 (s, 3H), 2.49 (s, 3H); ^{13}C NMR (150 MHz, CDCl_3) δ 165.7, 164.2, 163.9, 158.4, 154.2, 146.9, 135.4, 132.5, 127.4, 127.4, 127.1, 126.5, 121.8, 121.4, 120.6, 109.0, 56.3, 21.2; MS (EI) 335 (M^+); HRMS (ESI) m/z calcd for $\text{C}_{18}\text{H}_{14}\text{ClN}_3\text{O}_4^+$ ($\text{M}+\text{H}$) $^+$ 336.0979, found 336.0978. The enantiomeric ratio was determined by Daicel Chiralcel AD-H (0.46 cm $\times$ 25 cm), Hexanes/IPA = 80/20, 1.0 mL/min, $\lambda = 254$ nm, t (minor) = 22.2 min, t (major) = 31.9 min; IR: 3008, 2925, 1749, 1704, 1091.




(Sa)-4-Bromo-2-(2-methyl-4-oxoquinazolin-3(4H)-yl)isoindoline-1,3-dione (3ap):




Flash column chromatography on silica gel (ethyl acetate/petroleum ether, 1:2) gave the product (22.8 mg, 59% yield) as a yellow solid: mp 187.9-193.3 °C; $[\alpha]_D^{25} = 20.40$ (c = 0.20 in MeCN, 80% ee); ^1H NMR (CDCl_3 , 600 MHz) δ 8.17 (d, $J = 7.8$ Hz, 1H), 8.16 (s, 1H), 8.04 (d, $J = 8.4$ Hz, 1H), 7.88 (d, $J = 7.8$ Hz, 1H), 7.81 (t, $J = 7.8$ Hz, 1H), 7.72 (d, $J = 7.8$ Hz, 1H), 7.50 (t, $J = 7.2$ Hz, 1H), 2.49 (s, 3H); ^{13}C NMR (150 MHz, CDCl_3) δ 163.4, 162.9, 158.2, 153.7, 146.8, 138.5, 135.5, 131.4, 130.6, 128.3, 127.9, 127.5, 127.4, 127.3, 125.9, 120.5, 21.1; MS (EI) 382 (M^+); HRMS (ESI) m/z calcd for $\text{C}_{18}\text{H}_{10}\text{FN}_3\text{O}_3^+$ ($\text{M}+\text{H}$) $^+$ 383.9978, found 383.9978. The enantiomeric ratio was determined by Daicel Chiralcel AD-H (0.46 cm $\times$ 25 cm), Hexanes/IPA = 80/20, 1.0 mL/min, $\lambda = 254$ nm, t (minor) = 32.0 min, t (major) = 34.3 min; IR: 3089, 2925, 1745, 1700, 692.




(Sa)-3-Fluoro-2-(2-methyl-4-oxoquinazolin-3(4H)-yl)isoindoline-1,3-dione (3aq):




Flash column chromatography on silica gel (ethyl acetate/petroleum ether, 1:2) gave the product (22.3 mg, 69% yield) as a yellow solid: mp 173.0-176.7 °C; $[\alpha]_D^{25} = 11.40$ (c = 0.20 in MeCN, 46% ee); ^1H NMR (CDCl_3 , 600 MHz) δ 8.21 (d, $J = 7.8$ Hz, 1H), 7.91-7.87 (m, 1H), 7.83 (d, $J = 7.8$ Hz, 1H), 7.80 (d, $J = 7.8$ Hz, 1H), 7.71 (d, $J = 7.8$ Hz, 1H), 7.54 (t, $J = 8.4$ Hz, 1H), 7.49 (t, $J = 7.8$ Hz, 1H), 2.5 (s, 3H); ^{13}C NMR (150 MHz, CDCl_3) δ 163.1 (d, $J = 3.0$ Hz), 160.7, 158.2, 158.1 (d, $J = 256.5$ Hz), 153.8, 146.8, 138.1 (d, $J = 7.5$ Hz), 135.5, 131.7, 127.4, 127.4, 127.2, 123.7 (d, $J = 19.5$ Hz), 120.9 (d, $J = 3.0$ Hz), 120.4, 116.2, 21.1; MS (EI) 323 (M^+); HRMS (ESI) m/z calcd for $\text{C}_{17}\text{H}_{11}\text{FN}_3\text{O}_3^+$ ($\text{M}+\text{H}$) $^+$ 324.0779, found 324.0778. The enantiomeric ratio was determined by Daicel Chiralcel AD-H (0.46 cm $\times$ 25 cm), Hexanes/IPA = 80/20, 1.0 mL/min, $\lambda = 254$ nm, t (minor) = 34.4 min, t (major) = 39.0 min; IR: 3075, 2923, 1743, 1710, 906.




(Sa)-4-Methyl-2-(2-methyl-4-oxoquinazolin-3(4H)-yl)isoindoline-1,3-dione (3ar):




Flash column chromatography on silica gel (ethyl acetate/petroleum ether, 1:2) gave the product (25.5 mg, 80% yield) as a yellow solid: mp 212.5-217.7 °C; $[\alpha]_D^{25} = 43.20$ ($c = 0.10$ in MeCN, 80% ee); ^1H NMR (CDCl_3 , 600 MHz) δ 8.21 (d, $J = 7.8$ Hz, 1H), 7.89 (d, $J = 7.2$ Hz, 1H), 7.81 (s, 1H), 7.79 (d, $J = 7.8$ Hz, 1H), 7.71 (d, $J = 8.4$ Hz, 1H), 7.67 (d, $J = 8.4$ Hz, 1H), 7.48 (t, $J = 7.2$ Hz, 1H), 2.58 (s, 3H), 2.49 (s, 3H); ^{13}C NMR (150 MHz, CDCl_3) δ 164.3, 164.2, 158.3, 154.2, 147.1, 146.9, 135.9, 135.3, 130.2, 127.4, 127.3, 127.3, 127.1, 125.1, 124.5, 120.5, 22.2, 21.1; MS (EI) 319 (M^+); HRMS (ESI) m/z calcd for $\text{C}_{18}\text{H}_{14}\text{N}_3\text{O}_3^+$ ($\text{M}+\text{H}$) $^+$ 320.1030, found 320.1028. The enantiomeric ratio was determined by Daicel Chiralcel AD-H (0.46 cm $\times$ 25 cm), Hexanes/IPA = 80/20, 1.0 mL/min, $\lambda = 254$ nm, t (minor) = 21.4 min, t (major) = 31.1 min; IR: 3019, 2925, 1751, 1704, 1384.




(Sa)-3-Methyl-2-(2-methyl-4-oxoquinazolin-3(4H)-yl)isoindoline-1,3-dione (3as):




Flash column chromatography on silica gel (ethyl acetate/petroleum ether, 1:2) gave the product (11.8 mg, 37% yield) as a yellow solid: mp 129.0-134.2 °C; $[\alpha]_D^{25} = -41.80$ ($c = 0.10$ in MeCN, 45% ee); ^1H NMR (CDCl_3 , 600 MHz) δ 8.22 (dd, $J_1 = 1.2$ Hz, $J_2 = 7.8$ Hz, 1H), 7.84 (d, $J = 7.8$ Hz, 1H), 7.83-7.80 (m, 1H), 7.74 (d, $J = 7.8$ Hz, 1H), 7.72 (d, $J = 7.8$ Hz, 1H), 7.63 (d, $J = 7.8$ Hz, 1H), 7.49 (t, $J = 7.2$ Hz, 1H), 2.76 (s, 3H), 2.50 (s, 3H); ^{13}C NMR (150 MHz, CDCl_3) δ 164.7, 164.2, 158.3, 154.2, 146.9, 139.6, 137.7, 135.4, 134.9, 130.3, 127.4, 127.3, 127.1, 126.8, 122.3, 120.6, 21.2, 17.9; MS (EI) 319 (M^+); HRMS (ESI) m/z calcd for $\text{C}_{18}\text{H}_{14}\text{N}_3\text{O}_3^+$ ($\text{M}+\text{H}$) $^+$ 320.1030, found 320.1028. The enantiomeric ratio was determined by Daicel Chiralcel AD-H (0.46 cm $\times$ 25 cm), Hexanes/IPA = 80/20, 1.0 mL/min, $\lambda = 254$ nm, t (minor) = 11.7 min, t (major) = 12.9 min; IR: 3191, 2923, 1743, 1700, 1374.



(*Ra*)-2-(2-methyl-4-oxoquinazolin-3(4*H*)-yl)-5-(phenylethynyl)isoindoline-1,3-dione (7):





Flash column chromatography on silica gel (ethyl acetate/petroleum ether, 10:1) gave the product (27.4 mg, 72% yield) as a yellow solid mp 178.0-179.8 °C; $[\alpha]_D^{25} = -58.80$ ($c = 0.10$ in MeCN, 45% ee); ^1H NMR (CDCl_3 , 600 MHz) δ 8.23 (d, $J = 8.4$ Hz, 2H), 8.08 (s, 2H), 7.82 (t, $J = 7.8$ Hz, 1H), 7.73 (d, $J = 8.4$ Hz, 1H), 7.67 (d, $J = 7.2$ Hz, 2H), 7.54 (t, $J = 7.8$ Hz, 2H), 7.50 (t, $J = 7.2$ Hz, 2H), 2.53 (s, 3H); ^{13}C NMR (150 MHz, CDCl_3) δ 163.3, 163.1, 157.3, 153.6, 148.0, 145.8, 137.6, 134.5, 134.4, 132.9, 129.7, 128.4, 128.1, 127.2, 126.4, 126.1, 124.1, 122.1, 119.5, 20.2; MS (EI) 382 (M^+); HRMS (ESI) m/z calcd for $\text{C}_{23}\text{H}_{16}\text{N}_3\text{O}_3^+$ (M^+H^+) $^+$ 382.1186, found 382.1187. The enantiomeric ratio was determined by Daicel Chiralcel AD-H (0.46 cm $\times$ 25 cm), Hexanes/IPA = 80/20, 1.0 mL/min, $\lambda = 254$ nm, t (minor) = 32.2 min, t (major) = 38.2 min; IR: 3089, 2964, 1749, 1702, 1261.





7. Copies of the ^1H NMR and ^{13}C NMR Spectra.



5-Chloro-2-iodo-*N*-(2-methyl-4-oxoquinazolin-3(4*H*)-yl)benzamide (1a)





2-Iodo-5-methoxy-*N*-(2-methyl-4-oxoquinazolin-3(4*H*)-yl)benzamide (1b)





2-Iodo-5-methyl-N-(2-methyl-4-oxoquinazolin-3(4*H*)-yl)benzamide (1c)





5-Bromo-2-iodo-*N*-(2-methyl-4-oxoquinazolin-3(4*H*)-yl)benzamide (1d)





2-Iodo-N-(2-methyl-4-oxoquinazolin-3(4*H*)-yl)-5-(trifluoromethyl)benzamide (1e)





5-Fluoro-2-iodo-N-(2-methyl-4-oxoquinazolin-3(4*H*)-yl)benzamide (1f)





Methyl 3-(5-chloro-2-iodobenzamido)-4-oxo-3,4-dihydroquinazoline-2-carboxylate (1g)





Ethyl 3-(5-chloro-2-iodobenzamido)-4-oxo-3,4-dihydroquinazoline-2-carboxylate (1h)





Butyl 3-(5-chloro-2-iodobenzamido)-4-oxo-3,4-dihydroquinazoline-2-carboxylate (1i)





Benzyl 3-(5-chloro-2-iodobenzamido)-4-oxo-3,4-dihydroquinazoline-2-carboxylate (1j)





5-Chloro-*N*-(2-ethyl-4-oxoquinazolin-3(4*H*)-yl)-2-iodobenzamide (1k):





4-Chloro-2-iodo-N-(2-methyl-4-oxoquinazolin-3(4*H*)-yl)benzamide (1l)





2-Iodo-N-(2-methyl-4-oxoquinazolin-3(4H)-yl)-4-(trifluoromethyl)benzamide (m)





4-Fluoro-2-iodo-*N*-(2-methyl-4-oxoquinazolin-3(4*H*)-yl)benzamide (1n)





2-Iodo-4-methoxy-*N*-(2-methyl-4-oxoquinazolin-3(4*H*)-yl)benzamide (1o)





4-Bromo-2-iodo-*N*-(2-methyl-4-oxoquinazolin-3(4*H*)-yl)benzamide (1p)







3-Fluoro-2-iodo-*N*-(2-methyl-4-oxoquinazolin-3(4*H*)-yl)benzamide (1q)



2-Iodo-4-methyl-N-(2-methyl-4-oxoquinazolin-3(4*H*)-yl)benzamide (1r)





4-Iodo-3-methyl-N-(2-methyl-4-oxoquinazolin-3(4H)-yl)benzamide (1s)






Characterization Data for the Products

(*Ra*)-5-Chloro-2-(2-methyl-4-oxoquinazolin-3(4*H*)-yl)isoindoline-1,3-dione (3aa)





(*Ra*)-5-Methoxy-2-(2-methyl-4-oxoquinazolin-3(4*H*)-yl)isoindoline-1,3-dione (3ab)









(*Ra*)-5-Methyl-2-(2-methyl-4-oxoquinazolin-3(4*H*)-yl)isoindoline-1,3-dione (3ac)





(*Ra*)-5-Bromo-2-(2-methyl-4-oxoquinazolin-3(4*H*)-yl)isoindoline-1,3-dione (3ad)





(*Ra*)-2-(2-Methyl-4-oxoquinazolin-3(4*H*)-yl)-5-(trifluoromethyl)isoindoline-1,3-dione (3ae)





(*Ra*)-5-Fluoro-2-(2-methyl-4-oxoquinazolin-3(4*H*)-yl)isoindoline-1,3-dione (3af)





(Ra)-Methyl 3-(5-chloro-1,3-dioxisoindolin-2-yl)-4-oxo-3,4-dihydroquinazoline-2-carboxylate (3ag)







(*Ra*)-Ethyl 3-(5-chloro-1,3-dioxisoindolin-2-yl)-4-oxo-3,4-dihydroquinazoline-2-carboxylate (3ah)





(*Ra*)-Butyl 3-(5-chloro-1,3-dioxisoindolin-2-yl)-4-oxo-3,4-dihydroquinazoline-2-carboxylate (3ai)





(*Ra*)-Benzyl 3-(5-chloro-1,3-dioxisoindolin-2-yl)-4-oxo-3,4-dihydroquinazoline-2-carboxylate (3aj)





(*Ra*)-5-Chloro-2-(2-ethyl-4-oxoquinazolin-3(4*H*)-yl)isoindoline-1,3-dione (3ak):





(Sa)-4-Chloro-2-(2-methyl-4-oxoquinazolin-3(4*H*)-yl)isoindoline-1,3-dione (3ak)




(Sa)-2-(2-Methyl-4-oxoquinazolin-3(4*H*)-yl)-4-(trifluoromethyl)isoindoline-1,3-dione (3al)




(Sa)-4-Fluoro-2-(2-methyl-4-oxoquinazolin-3(4H)-yl)isoindoline-1,3-dione (3am)





8.220
8.206
7.923
7.909





(Sa)-4-Methoxy-2-(2-methyl-4-oxoquinazolin-3(4H)-yl)isoindoline-1,3-dione (3an)





(Sa)-4-Bromo-2-(2-methyl-4-oxoquinazolin-3(4*H*)-yl)isoindoline-1,3-dione (3ao)





(*Sa*)-3-Fluoro-2-(2-methyl-4-oxoquinazolin-3(4*H*)-yl)isoindoline-1,3-dione (3ap)



(Sa)-4-Methyl-2-(2-methyl-4-oxoquinazolin-3(4*H*)-yl)isoindoline-1,3-dione (3aq)



(Sa)-3-Methyl-2-(2-methyl-4-oxoquinazolin-3(4*H*)-yl)isoindoline-1,3-dione (3ar)



(*Ra*)-2-(2-methyl-4-oxoquinazolin-3(4*H*)-yl)-5-(phenylethynyl)isoindoline-1,3-dione (7)

